AstraZeneca has determined to discontinue the STABILIZE-CKD and DIALIZE-Outcomes Section III proof research for Lokelma (sodium zirconium cyclosilicate). This determination was made as a result of considerably longer enrollment timelines and low incident charges, respectively, making it prohibitively costly to ship analysis ends in a timeframe to meaningfully advance medical apply. The STABILIZE-CKD and DIALIZE-Outcomes research are a part of […]
